Short answer
Zymeworks Inc. (ZYME) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results announced for the three months ended June 30, 2026.
Zymeworks Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced for the three months ended June 30, 2026
- Full results and management commentary available in Exhibit 99.1
- August 6, 2026 release date provides the market’s latest operating update
Item 7.01 · Regulation FD Disclosure
- Zymeworks identifies SEC filings, press releases, investor sites, conferences, and social media as potential sources of material information
- Investors should monitor official company channels beyond 8-K filings for updates on product candidates and corporate matters
- Disclosure expands the company’s Regulation FD communication framework across X, LinkedIn, and investor-relations platforms
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue fell to $4.6M from $48.7M, reflecting absence of prior-year nonrecurring collaboration revenue
- Net loss widened to $45.0M from $2.3M, pressured by lower revenue and $6.6M Royalty Pharma interest expense
- Zanidatamab’s August 25 U.S. PDUFA date represents a potential $250M approval milestone and up to $190M additional global milestones
- Theravance acquisition expected in 2H 2026, adding ~$60M annualized YUPELRI cash flow and $2.5B Irish tax attributes
- Cash resources totaled $322.5M; $49.4M used for repurchases under the $125.0M 2026 authorization
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Zymeworks Inc. 8-K filings
Get the next ZYME 8-K as it lands
Follow ZYME for push alerts, or ask the research agent what this filing means.